Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

To join this study, you would need to be at least 18 years old and have a confirmed diagnosis of certain advanced solid tumours that cannot be cured by current standard treatments. Specifically, your tumour must show a particular genetic weakness called 'homologous recombination deficiency' (HR-deficient).

If you are considered for MOMA-313 on its own, your tumour needs to be HR-deficient. If you are considered for MOMA-313 combined with Olaparib, your tumour also needs to be HR-deficient, and you might have been treated with a PARP inhibitor before or be new to this type of treatment, depending on which part of the study you join. You must also be well enough to take part, meaning you can look after yourself and have healthy enough organ function.

There are also reasons why you might not be able to join. For example, if you have another active cancer, significant heart problems, uncontrolled spread of cancer to the brain, signs of an active infection, or if you have previously taken a similar drug to MOMA-313. Women who are pregnant or breastfeeding cannot participate. Your doctors will review your full medical history to ensure the study is safe and appropriate for you.

If you decide to take part in this study, you will first undergo a thorough check-up to make sure you meet all the criteria. This will involve examinations, blood tests, and scans. You will receive MOMA-313 as an oral medication (a pill). Depending on which group you are in, you might also take Olaparib pills.

Throughout the study, you will have regular clinic visits. During these visits, doctors will monitor your health closely, check for any side effects, take blood and other samples, and perform scans to see how your cancer is responding. The number of visits and the assessments will be more frequent at the beginning of the treatment to carefully monitor the new drug. Initially, doses of MOMA-313 will be slowly increased in small groups of patients until the safest and most effective dose is found. After treatment, there will be a follow-up period to continue monitoring your health and any long-term effects. The total length of your participation will depend on how you respond to the treatment and the study's design, but typically involves active treatment followed by a period of observation.